Analysis Ocugen’s Long Game: A Phase 3 Enrollment, a Regulatory Green Light, and a Market That Won’t Wait
Biotech investing has always demanded a rare commodity: patience. Ocugen is currently testing just how much of it shareholders are willing to spare. Between a regulatory path that has been...